Usefulness and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (from the TRACER trial)

Marco Valgimigli, Pierluigi Tricoci, Zhen Huang, Philip E. Aylward, Paul W. Armstrong, Frans Van De Werf, Sergio Leonardi, Harvey D. White, Petr Widimsky, Robert A. Harrington, Angel Cequier, Edmond Chen, Yuliya Lokhnygina, Lars Wallentin, John Strony, Kenneth W. Mahaffey, David J. Moliterno

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The therapeutic potential of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (PCI) is unknown. This prespecified analysis of a postrandomization subgroup evaluated the effects of vorapaxar compared with placebo among Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) participants undergoing PCI, focusing on the implanted stent type (drug-eluting stent [DES] vs bare-metal stent [BMS]). Among 12,944 recruited patients, 7,479 (57.8%) underwent PCI during index hospitalization, and 3,060 (40.9%) of those patients received exclusively BMS, whereas 4,015 (53.7%) received DES. The median (twenty-fifth, seventy-fifth percentiles) duration of thienopyridine therapy was 133 days (47, 246) with BMS and 221 days (88, 341) with DES. At 2 years among patients undergoing PCI, the primary (cardiovascular death, myocardial infarction, stroke, recurrent ischemia with rehospitalization, or urgent coronary revascularization) and secondary (cardiovascular death, myocardial infarction, or stroke) end points did not differ between vorapaxar and placebo groups, which was consistent with the treatment effect observed in the overall study population (p value for interaction = 0.540). However, the treatment effect trended greater (p value for interaction = 0.069) and the risk for bleeding in patients taking vorapaxar versus placebo appeared attenuated in BMS-only recipients. After adjustment for confounders, the interaction was no longer significant (p value = 0.301). The covariate that mostly explained the stent-type-by-treatment interaction was the duration of clopidogrel therapy. In conclusion, among patients with PCI, the effect of vorapaxar is consistent with the overall TRACER results. Patients who received a BMS underwent shorter courses of clopidogrel therapy and displayed trends toward greater ischemic benefit from vorapaxar and lesser bleeding risk, compared with patients who received a DES.

Original languageEnglish
Pages (from-to)665-673
Number of pages9
JournalThe American Journal of Cardiology
Volume114
Issue number5
DOIs
Publication statusPublished - Sep 1 2014

Fingerprint

Percutaneous Coronary Intervention
Acute Coronary Syndrome
Stents
Safety
Drug-Eluting Stents
clopidogrel
Metals
Placebos
Therapeutics
Stroke
Myocardial Infarction
Hemorrhage
Thrombin Receptors
vorapaxar
Hospitalization
Ischemia
Population

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Usefulness and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (from the TRACER trial). / Valgimigli, Marco; Tricoci, Pierluigi; Huang, Zhen; Aylward, Philip E.; Armstrong, Paul W.; Van De Werf, Frans; Leonardi, Sergio; White, Harvey D.; Widimsky, Petr; Harrington, Robert A.; Cequier, Angel; Chen, Edmond; Lokhnygina, Yuliya; Wallentin, Lars; Strony, John; Mahaffey, Kenneth W.; Moliterno, David J.

In: The American Journal of Cardiology, Vol. 114, No. 5, 01.09.2014, p. 665-673.

Research output: Contribution to journalArticle

Valgimigli, M, Tricoci, P, Huang, Z, Aylward, PE, Armstrong, PW, Van De Werf, F, Leonardi, S, White, HD, Widimsky, P, Harrington, RA, Cequier, A, Chen, E, Lokhnygina, Y, Wallentin, L, Strony, J, Mahaffey, KW & Moliterno, DJ 2014, 'Usefulness and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (from the TRACER trial)', The American Journal of Cardiology, vol. 114, no. 5, pp. 665-673. https://doi.org/10.1016/j.amjcard.2014.05.054
Valgimigli, Marco ; Tricoci, Pierluigi ; Huang, Zhen ; Aylward, Philip E. ; Armstrong, Paul W. ; Van De Werf, Frans ; Leonardi, Sergio ; White, Harvey D. ; Widimsky, Petr ; Harrington, Robert A. ; Cequier, Angel ; Chen, Edmond ; Lokhnygina, Yuliya ; Wallentin, Lars ; Strony, John ; Mahaffey, Kenneth W. ; Moliterno, David J. / Usefulness and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (from the TRACER trial). In: The American Journal of Cardiology. 2014 ; Vol. 114, No. 5. pp. 665-673.
@article{702466a259f643448b3ced6c6f755125,
title = "Usefulness and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (from the TRACER trial)",
abstract = "The therapeutic potential of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (PCI) is unknown. This prespecified analysis of a postrandomization subgroup evaluated the effects of vorapaxar compared with placebo among Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) participants undergoing PCI, focusing on the implanted stent type (drug-eluting stent [DES] vs bare-metal stent [BMS]). Among 12,944 recruited patients, 7,479 (57.8{\%}) underwent PCI during index hospitalization, and 3,060 (40.9{\%}) of those patients received exclusively BMS, whereas 4,015 (53.7{\%}) received DES. The median (twenty-fifth, seventy-fifth percentiles) duration of thienopyridine therapy was 133 days (47, 246) with BMS and 221 days (88, 341) with DES. At 2 years among patients undergoing PCI, the primary (cardiovascular death, myocardial infarction, stroke, recurrent ischemia with rehospitalization, or urgent coronary revascularization) and secondary (cardiovascular death, myocardial infarction, or stroke) end points did not differ between vorapaxar and placebo groups, which was consistent with the treatment effect observed in the overall study population (p value for interaction = 0.540). However, the treatment effect trended greater (p value for interaction = 0.069) and the risk for bleeding in patients taking vorapaxar versus placebo appeared attenuated in BMS-only recipients. After adjustment for confounders, the interaction was no longer significant (p value = 0.301). The covariate that mostly explained the stent-type-by-treatment interaction was the duration of clopidogrel therapy. In conclusion, among patients with PCI, the effect of vorapaxar is consistent with the overall TRACER results. Patients who received a BMS underwent shorter courses of clopidogrel therapy and displayed trends toward greater ischemic benefit from vorapaxar and lesser bleeding risk, compared with patients who received a DES.",
author = "Marco Valgimigli and Pierluigi Tricoci and Zhen Huang and Aylward, {Philip E.} and Armstrong, {Paul W.} and {Van De Werf}, Frans and Sergio Leonardi and White, {Harvey D.} and Petr Widimsky and Harrington, {Robert A.} and Angel Cequier and Edmond Chen and Yuliya Lokhnygina and Lars Wallentin and John Strony and Mahaffey, {Kenneth W.} and Moliterno, {David J.}",
year = "2014",
month = "9",
day = "1",
doi = "10.1016/j.amjcard.2014.05.054",
language = "English",
volume = "114",
pages = "665--673",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Usefulness and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (from the TRACER trial)

AU - Valgimigli, Marco

AU - Tricoci, Pierluigi

AU - Huang, Zhen

AU - Aylward, Philip E.

AU - Armstrong, Paul W.

AU - Van De Werf, Frans

AU - Leonardi, Sergio

AU - White, Harvey D.

AU - Widimsky, Petr

AU - Harrington, Robert A.

AU - Cequier, Angel

AU - Chen, Edmond

AU - Lokhnygina, Yuliya

AU - Wallentin, Lars

AU - Strony, John

AU - Mahaffey, Kenneth W.

AU - Moliterno, David J.

PY - 2014/9/1

Y1 - 2014/9/1

N2 - The therapeutic potential of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (PCI) is unknown. This prespecified analysis of a postrandomization subgroup evaluated the effects of vorapaxar compared with placebo among Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) participants undergoing PCI, focusing on the implanted stent type (drug-eluting stent [DES] vs bare-metal stent [BMS]). Among 12,944 recruited patients, 7,479 (57.8%) underwent PCI during index hospitalization, and 3,060 (40.9%) of those patients received exclusively BMS, whereas 4,015 (53.7%) received DES. The median (twenty-fifth, seventy-fifth percentiles) duration of thienopyridine therapy was 133 days (47, 246) with BMS and 221 days (88, 341) with DES. At 2 years among patients undergoing PCI, the primary (cardiovascular death, myocardial infarction, stroke, recurrent ischemia with rehospitalization, or urgent coronary revascularization) and secondary (cardiovascular death, myocardial infarction, or stroke) end points did not differ between vorapaxar and placebo groups, which was consistent with the treatment effect observed in the overall study population (p value for interaction = 0.540). However, the treatment effect trended greater (p value for interaction = 0.069) and the risk for bleeding in patients taking vorapaxar versus placebo appeared attenuated in BMS-only recipients. After adjustment for confounders, the interaction was no longer significant (p value = 0.301). The covariate that mostly explained the stent-type-by-treatment interaction was the duration of clopidogrel therapy. In conclusion, among patients with PCI, the effect of vorapaxar is consistent with the overall TRACER results. Patients who received a BMS underwent shorter courses of clopidogrel therapy and displayed trends toward greater ischemic benefit from vorapaxar and lesser bleeding risk, compared with patients who received a DES.

AB - The therapeutic potential of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (PCI) is unknown. This prespecified analysis of a postrandomization subgroup evaluated the effects of vorapaxar compared with placebo among Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) participants undergoing PCI, focusing on the implanted stent type (drug-eluting stent [DES] vs bare-metal stent [BMS]). Among 12,944 recruited patients, 7,479 (57.8%) underwent PCI during index hospitalization, and 3,060 (40.9%) of those patients received exclusively BMS, whereas 4,015 (53.7%) received DES. The median (twenty-fifth, seventy-fifth percentiles) duration of thienopyridine therapy was 133 days (47, 246) with BMS and 221 days (88, 341) with DES. At 2 years among patients undergoing PCI, the primary (cardiovascular death, myocardial infarction, stroke, recurrent ischemia with rehospitalization, or urgent coronary revascularization) and secondary (cardiovascular death, myocardial infarction, or stroke) end points did not differ between vorapaxar and placebo groups, which was consistent with the treatment effect observed in the overall study population (p value for interaction = 0.540). However, the treatment effect trended greater (p value for interaction = 0.069) and the risk for bleeding in patients taking vorapaxar versus placebo appeared attenuated in BMS-only recipients. After adjustment for confounders, the interaction was no longer significant (p value = 0.301). The covariate that mostly explained the stent-type-by-treatment interaction was the duration of clopidogrel therapy. In conclusion, among patients with PCI, the effect of vorapaxar is consistent with the overall TRACER results. Patients who received a BMS underwent shorter courses of clopidogrel therapy and displayed trends toward greater ischemic benefit from vorapaxar and lesser bleeding risk, compared with patients who received a DES.

UR - http://www.scopus.com/inward/record.url?scp=84908372736&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908372736&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2014.05.054

DO - 10.1016/j.amjcard.2014.05.054

M3 - Article

VL - 114

SP - 665

EP - 673

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 5

ER -